Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
48 hedge funds and large institutions have $49.5M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 10 closing their positions.
26% more capital invested
Capital invested by funds: $39.1M → $49.5M (+$10.3M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
4% more funds holding
Funds holding: 46 → 48 (+2)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.22M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$843K |
| 3 |
JP Morgan Chase
New York
|
+$386K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$337K |
| 5 |
PP
PDT Partners
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$803K |
| 2 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$331K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$165K |
| 4 |
B
Bailard
Foster City,
California
|
-$150K |
| 5 |
VF
Virtu Financial
New York
|
-$125K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
B
51
Bailard
Foster City,
California
| – | -$150K | -38,600 | Closed |
|
|
AIM
52
Alambic Investment Management
Belvedere,
California
| – | -$81K | -20,711 | Closed |
|
53
Jane Street
New York
| – | -$76K | -19,640 | Closed |
|
|
QSS
54
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$55K | -14,195 | Closed |
|
|
CPIG
55
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$52K | -14,081 | Closed |
|
|
BAM
56
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$39K | -10,143 | Closed |
|
|
ED
57
Exane Derivatives
Paris,
France
| – | -$15.9K | -4,078 | Closed |
|
|
PFS
58
Prospera Financial Services
Dallas,
Texas
| – | -$4K | -1,139 | Closed |
|
STSA Hedge Fund Activity: Q4 2020 in Review
48 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q4 2020, worth a combined $49.5M — up 26% from $39.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STSA positions and 10 closed out — a net gain of 2 holders — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.22M. The largest seller was Two Sigma Investments, cutting an estimated $803K.
- 48 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q4 2020, up from 46 in Q3 2020.
- Funds reported $49.5M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 26% quarter-over-quarter.
- 12 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +2 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Morgan Stanley, an estimated $3.22M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Two Sigma Investments, an estimated $803K sold.
Based on aggregated 13F filings for Q4 2020.